[1]

World Health Organization. 2021. Reducing the burden of noncommunicable diseases through strengthening prevention and control of diabetes (WHA74.4). https://apps.who.int/gb/ebwha/pdf_files/WHA74/A74_R4-en.pdf (accessed on 16 July 2026)
[2]

Tan TE, Wong TY. 2023. Diabetic retinopathy: looking forward to 2030. Frontiers in Endocrinology 13:1077669

doi: 10.3389/fendo.2022.1077669
[3]

Hirsch IB, Brownlee M. 2010. Beyond hemoglobin A1c—need for additional markers of risk for diabetic microvascular complications. JAMA 303(22):2291−2292

doi: 10.1001/jama.2010.785
[4]

Fong DS, Ferris FL, Davis MD, Chew EY. 1999. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. American Journal of Ophthalmology 127:137−141

doi: 10.1016/s0002-9394(98)00309-2
[5]

Simó R, Hernández C. 2008. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 51:1574−1580

doi: 10.1007/s00125-008-0989-9
[6]

Porta M, Striglia E. 2020. Intravitreal anti-VEGF agents and cardiovascular risk. Internal and Emergency Medicine 15(2):199−210

doi: 10.1007/s11739-019-02253-7
[7]

Gan WZ, Ramachandran V, Lim CSY, Koh RY. 2019. Omics-based biomarkers in the diagnosis of diabetes. Journal of Basic and Clinical Physiology and Pharmacology 31(2):20190120

doi: 10.1515/jbcpp-2019-0120
[8]

Olivier M, Asmis R, Hawkins GA, Howard TD, Cox LA. 2019. The need for multi-omics biomarker signatures in precision medicine. International Journal of Molecular Sciences 20(19):4781

doi: 10.3390/ijms20194781
[9]

Aderemi AV, Ayeleso AO, Oyedapo OO, Mukwevho E. 2021. Metabolomics: a scoping review of its role as a tool for disease biomarker discovery in selected non-communicable diseases. Metabolites 11(7):418

doi: 10.3390/metabo11070418
[10]

Xuan Q, Ouyang Y, Wang Y, Wu L, Li H, et al. 2020. Multiplatform metabolomics reveals novel serum metabolite biomarkers in diabetic retinopathy subjects. Advanced Science 7(22):2001714

doi: 10.1002/advs.202001714
[11]

Huang X, Li Y, Guo T, Mo Z, Chi M, et al. 2025. 增生型糖尿病视网膜病变伴玻璃体视网膜异常粘连患者的玻璃体液代谢特征[Metabolic characteristics of vitreous fluid in patients with proliferative diabetic retinopathy with abnormal vitreoretinal adhesion]. 眼科新进展[Ophthalmology and New Advances] 45:799−804 (in Chinese)

doi: 10.13389/j.cnki.rao.2025.0137
[12]

Shea TB, Rogers E. 2014. Lifetime requirement of the methionine cycle for neuronal development and maintenance. Current Opinion in Psychiatry 27(2):138−142

doi: 10.1097/YCO.0000000000000046
[13]

Tassinari V, Jia W, Chen WL, Candi E, Melino G. 2024. The methionine cycle and its cancer implications. Oncogene 43(48):3483−3488

doi: 10.1038/s41388-024-03122-0
[14]

Zeng Y, Liu M, Li M, Wei D, Mao M, et al. 2023. Early changes to retinal structure in patients with diabetic retinopathy as determined by ultrawide swept-source optical coherence tomography-angiography. Frontiers in Endocrinology 14:1143535

doi: 10.3389/fendo.2023.1143535
[15]

Brazionis L, Rowley KS, Itsiopoulos C, Harper CA, O'Dea K. 2008. Homocysteine and diabetic retinopathy. Diabetes Care 31(1):50−56

doi: 10.2337/dc07-0632
[16]

Lee YJ, Chiu CC, Ke CY, Tien N, Lin PK. 2017. Homocysteine facilitates prominent polygonal angiogenetic networks of a choroidal capillary sprouting model. Investigative Ophthalmology & Visual Science 58:4332−4343

doi: 10.1167/iovs.17-22308
[17]

Mohammad G, Kowluru RA. 2020. Homocysteine disrupts balance between MMP-9 and its tissue inhibitor in diabetic retinopathy: the role of DNA methylation. International Journal of Molecular Sciences 21(5):1771

doi: 10.3390/ijms21051771
[18]

Lim CP, Loo AV, Khaw KW, Sthaneshwar P, Khang TF, et al. 2012. Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. British Journal of Ophthalmology 96(5):704−707

doi: 10.1136/bjophthalmol-2011-301044
[19]

Xu C, Wu Y, Liu G, Liu X, Wang F, et al. 2014. Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis. Diagnostic Pathology 9:167

doi: 10.1186/s13000-014-0167-y
[20]

Hermann A, Sitdikova G. 2021. Homocysteine: biochemistry, molecular biology and role in disease. Biomolecules 11(5):737

doi: 10.3390/biom11050737
[21]

Dobrijević D, Pastor K, Nastić N, Özogul F, Krulj J, et al. 2023. Betaine as a functional ingredient: metabolism, health-promoting attributes, food sources, applications and analysis methods. Molecules 28(12):4824

doi: 10.3390/molecules28124824
[22]

Zhao G, He F, Wu C, Li P, Li N, et al. 2018. Betaine in inflammation: mechanistic aspects and applications. Frontiers in Immunology 9:1070

doi: 10.3389/fimmu.2018.01070
[23]

Dobrowolski L, Monchakivska AV, Rogozińska M, Kowalski K, Kuczeriszka M. 2026. Betaine alters the interplay of the adenosine and NO systems in the control of renal regional haemodynamics and excretion in diabetic female rats. International Journal of Molecular Sciences 27(9):4076

doi: 10.3390/ijms27094076
[24]

Yi EY, Kim YJ. 2012. Betaine inhibits in vitro and in vivo angiogenesis through suppression of the NF-κB and Akt signaling pathways. International Journal of Oncology 41(5):1879−1885

doi: 10.3892/ijo.2012.1616
[25]

Park SW, Jun HO, Kwon E, Yun JW, Kim JH, et al. 2017. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling. Vascular Pharmacology 90:19−26

doi: 10.1016/j.vph.2016.07.007
[26]

Niederleithner M, de Sisternes L, Stino H, Sedova A, Schlegl T, et al. 2023. Ultra-widefield OCT angiography. IEEE Transactions on Medical Imaging 42(4):1009−1020

doi: 10.1109/TMI.2022.3222638
[27]

Russell JF, Flynn-Jr HW, Sridhar J, Townsend JH, Shi Y, et al. 2019. Distribution of diabetic neovascularization on ultra-widefield fluorescein angiography and on simulated widefield OCT angiography. American Journal of Ophthalmology 207:110−120

doi: 10.1016/j.ajo.2019.05.031
[28]

Yu G, Aaberg MT, Patel TP, Iyengar RS, Powell C, et al. 2020. Quantification of retinal nonperfusion and neovascularization with ultrawidefield fluorescein angiography in patients with diabetes and associated characteristics of advanced disease. JAMA Ophthalmology 138(6):680−688

doi: 10.1001/jamaophthalmol.2020.1257
[29]

Waheed NK, Rosen RB, Jia Y, Munk MR, Huang D, et al. 2023. Optical coherence tomography angiography in diabetic retinopathy. Progress in Retinal and Eye Research 97:101206

doi: 10.1016/j.preteyeres.2023.101206
[30]

Lei X, Zeng G, Zhang Y, Li Q, Zhang J, et al. 2018. Association between homocysteine level and the risk of diabetic retinopathy: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome 10:61

doi: 10.1186/s13098-018-0362-1
[31]

Middleton TL, Constantino MI, Molyneaux L, D'Souza M, Twigg SM, et al. 2020. Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. Diabetic Medicine 37(6):991−999

doi: 10.1111/dme.14238
[32]

Li H, Wang B, Liu C. 2025. Association between age at diabetes diagnosis and the development and progression of diabetic retinopathy. Scientific Reports 15(1):13827

doi: 10.1038/s41598-025-98840-0
[33]

Arrigo A, Aragona E, Bandello F. 2022. VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Annals of Medicine 54(1):1089−1111

doi: 10.1080/07853890.2022.2064541
[34]

González-Lamuño D, Arrieta-Blanco FJ, Fuentes ED, Forga-Visa MT, Morales-Conejo M, et al. 2023. Hyperhomocysteinemia in adult patients: a treatable metabolic condition. Nutrients 16(1):135

doi: 10.3390/nu16010135
[35]

Awashra A, AbuBaha M, Istetieh K, Sandouka D, Aldwaik S, et al. 2026. B vitamins and cardiovascular health: mechanisms, clinical evidence, and precision prevention strategies. Nutrition & Metabolism 23(1):72

doi: 10.1186/s12986-026-01125-0
[36]

Wilson S, Siebourg-Polster J, Titz B, Jiang Z, Bartolo F, et al. 2023. Correlation of aqueous, vitreous, and serum protein levels in patients with retinal diseases. Translational Vision Science & Technology 12(11):9

doi: 10.1167/tvst.12.11.9
[37]

Antonetti DA. 2021. The neuroscience of diabetic retinopathy. Visual Neuroscience 38:E001

doi: 10.1017/S0952523820000115
[38]

Nian S, Lo ACY, Mi Y, Ren K, Yang D. 2021. Neurovascular unit in diabetic retinopathy: pathophysiological roles and potential therapeutical targets. Eye and Vision 8(1):15

doi: 10.1186/s40662-021-00239-1
[39]

Malaviya P, Kowluru RA. 2024. Diabetic retinopathy and regulation of mitochondrial glutathione-glutathione peroxidase axis in hyperhomocysteinemia. Antioxidants 13(3):254

doi: 10.3390/antiox13030254